Maravai LifeSciences Holdings, Inc.
MRVIHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeMaravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North. With a market capitalization of $2.67B, it sits in mid-cap territory. It operates through two segments: TRILINK and CYGNUS.
Market Cap
$2.67B
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
-78.92
EPS (TTM)
$-0.72
EPS (Fwd)
$-0.09
ROE
-41.0%
ROA
-6.6%
Cash
$165.9M
Total Debt
$315.0M
Free CF
-$11.3M
52W Change
197.9%
Annual Financials
Cash vs Debt
On the balance sheet, MRVI has $165.9M in cash with $315.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$11.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -41.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $883.0M (2022) to $185.7M (2025), a 79% decline worth watching.
With a beta below 0.7, Maravai LifeSciences Holdings, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MRVI.